ProCE Banner Activity

KEYNOTE-177 Final Analysis: First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC

Slideset Download
Conference Coverage
In the final analysis from KEYNOTE-177, first-line pembrolizumab was associated with an improved median OS compared with chemotherapy in patients with MSI-H/dMMR mCRC.

Released: June 17, 2021

Expiration: June 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme